[Giant infantile hepatic hemangioma: which therapeutic options?]

Cristina Gonçalves1, Luisa Lobo2, Rui Anjos3

  • 1Unidade de Gastrenterologia Pediátrica. Departamento de Pediatria. Hospital de Santa Maria. Centro Académico de Medicina de Lisboa. Lisboa. Portugal.

Acta Medica Portuguesa
|January 7, 2014
PubMed

Insights

Infantile hepatic hemangioma (IHH) in children can cause heart failure and Kasabach-Merritt syndrome, but may spontaneously regress. This case highlights a conservative approach for a large IHH with favorable outcomes.

Area of Science:

  • Pediatric Oncology
  • Hepatology
  • Vascular Anomalies

Background:

  • Infantile hepatic hemangioma (IHH) is a common pediatric liver tumor, particularly in infants under six months.
  • Treatment strategies for IHH require individualization based on clinical presentation and tumor characteristics.

Observation:

  • A 4-year-old boy presented with a large, vascular liver tumor diagnosed neonatally as IHH.
  • The patient experienced spontaneous regression of associated heart failure and Kasabach-Merritt syndrome (thrombocytopenia, anemia).

Findings:

  • Sequential imaging (ultrasound, MRI, CT) confirmed IHH and provided vascular mapping.
  • Progressive tumor regression was observed from the first year of life, supporting a conservative management approach.

Implications:

  • This case underscores the potential for spontaneous regression in large infantile hepatic hemangiomas, even with severe initial complications.
  • A conservative, observation-based strategy may be effective, though optimal therapeutic decisions for IHH require ongoing evaluation of individual patient factors and cost-effectiveness.